A recent study suggests that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who end traditional lifestyle programs.
Research printed in a prominent health publication shows that while obese people often shed a large proportion of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Users using these medications should be aware of the danger of quick rebound weight gain when the therapy concludes," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment weight within about 18 months.
Comparing Therapies
The research, which examined 37 of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with other pills.
The team note that people who shed pounds through lifestyle changes alone usually experience a more gradual weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Nutrition scientists propose the way of the injections explains the accelerated rebound.
These medications mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal may cause the body to produce less of its endogenous GLP-1, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making binge eating much more probable."
A Chronic Disease?
Health authorities recommend the injections for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, considering the significant potential of weight regain, the treatment might need to be life-long.
This perspective is echoed by drug manufacturers, who say that the findings "underscore the long-term nature of excess weight," akin to managing conditions like diabetes.
User Testimonies
Users who have come off the jabs describe a intense resurgence of appetite.
"I experienced a switch activating and you're instantly extremely hungry," described a patient.
The struggle is compounded if patients have not developed permanent lifestyle or habit changes during treatment.
Growing Use
Recent estimates suggest that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is more common among females compared to men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, experts emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent solution and lasting health benefits likely depends on ongoing behavioural management.
